Revision of PRECAUTIONS

Cefazolin sodium
Cefazolin sodium hydrate

August 29, 2023

Therapeutic category
Antibiotic preparations acting mainly on gram-positive and gram-negative bacteria

Non-proprietary name
Cefazolin sodium
Cefazolin sodium hydrate

Safety measure
PRECAUTIONS should be revised.
**Important Precautions**

Since no methods are currently available for predicting onset of shock or anaphylaxis associated with this drug with reasonable certainty, the following measures should be taken.

**Adverse Reactions**

**Clinically Significant Adverse Reactions**

(N/A)

---

**Revision**

Important Precautions

Since no methods are currently available for predicting onset of shock, anaphylaxis, or acute coronary syndrome accompanying allergic reaction associated with this drug with reasonable certainty, the following measures should be taken.

**Adverse Reactions**

**Clinically Significant Adverse Reactions**

Acute coronary syndrome accompanying allergic reaction:

Acute coronary syndrome accompanying allergic reaction may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.

---

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

---

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, PSEHB Notification No. 0611-1 by the Director-General of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.

<table>
<thead>
<tr>
<th>Current</th>
<th>Revision</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>8. IMPORTANT PRECAUTIONS</strong></td>
<td><strong>8. IMPORTANT PRECAUTIONS</strong></td>
</tr>
<tr>
<td>Since no methods are currently available for predicting onset of</td>
<td>Since no methods are currently available for predicting onset of</td>
</tr>
</tbody>
</table>

---

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan

E-mail: safety.info@pmda.go.jp
<table>
<thead>
<tr>
<th>shock or anaphylaxis associated with this drug with reasonable certainty, the following measures should be taken.</th>
<th>shock, anaphylaxis, or acute coronary syndrome accompanying allergic reaction associated with this drug with reasonable certainty, the following measures should be taken.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11. ADVERSE REACTIONS</strong></td>
<td><strong>11. ADVERSE REACTIONS</strong></td>
</tr>
<tr>
<td><strong>11.1 Clinically Significant Adverse Reactions</strong></td>
<td><strong>11.1 Clinically Significant Adverse Reactions</strong></td>
</tr>
<tr>
<td>(N/A)</td>
<td>Acute coronary syndrome accompanying allergic reaction</td>
</tr>
</tbody>
</table>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.